Aducanumab, sold under the brand name Aduhelm, is an intravenous medication used to treat Alzheimer's disease. Aducanumab was approved by the U.S. Food and Drug Administration (FDA) on June 7, 2021. This approval is notable because Aducanumab is the first treatment approved for Alzheimer's disease that targets and reduces amyloid-beta plaques in the brain, a hallmark of the disease.
Aducanumab is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment or at the mild dementia stage of the disease. The drug works by targeting amyloid-beta plaques in the brain, which are believed to contribute to the progression of Alzheimer's.
Aducanumab is administered as an intravenous infusion:
Common side effects of Aducanumab include:
Severe side effects may include:
Patients should seek immediate medical attention if they experience severe side effects.
ARIA Risk: Aducanumab can cause ARIA, which typically resolves over time but can be serious. Symptoms include headache, dizziness, nausea, confusion, and vision changes.
Pregnancy and Breastfeeding: It is not known if Aducanumab affects an unborn baby or passes into breast milk. Patients should inform their healthcare provider if they are pregnant or planning to become pregnant.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!